Primary outcome reporting in adolescent depression clinical trials needs standardization

Monsour, Andrea; Mew, Emma J.; Patel, Sagar; Chee-a-tow, Alyssandra; Saeed, Leena; Santos, Lucia; Courtney, Darren B.; Watson, Priya N.; Monga, Suneeta; Szatmari, Peter; Offringa, Martin; Butcher, Nancy J.

doi:10.1186/s12874-020-01019-6

BMC Medical Research Methodology

Table 1 Characteristics of included articles of randomized clinical trials assessing treatment interventions for adolescents with major depressive disorder (n = 18 trials)

From: Primary outcome reporting in adolescent depression clinical trials needs standardization

First author, year of publication [citation]	Intervention type^a	Age of included population (years)	Total sample size at enrolment	Length of follow-up (weeks)	Study site location	Funding source^b	Primary outcome
Cheung et al., 2008 [40]	Drug	13–19	22	52	North America	Government	Time to relapse
Goodyer et al., 2008 [41]	Drug and Psychosocial	11–17	208	28	Europe	Government	Global measure of current mental health status
Emslie et al., 2009 [42]	Drug	12–17	316	8	North America	Industry	Depressive symptom severity
Findling et al., 2009 [43]	Drug	12–17	34	8	North America	Not for Profit; Industry	Depressive symptom severity
Jacobs et al., 2010 [44]	Drug and Psychosocial	12–17	439	12	North America	Government	Oppositionality
Atkinson et al., 2014 [39]	Drug	7–17	337	36	North America	Industry	Depressive symptom severity
DelBello et al., 2014 [45]	Drug	12–17	308	12	North America	Industry	Depressive symptom severity
Emslie et al., 2014 [46]	Drug	7–17	448	36	North America	Industry	Depressive symptom severity
Richardson et al., 2014 [47]	Psychosocial	13–17	101	52	North America	Government	Depressive symptom severity
Szigethy et al., 2014 [37]	Psychosocial	9–17	217	12	North America	Government	Depressive symptom severity
Clarke et al., 2016 [38]	Psychosocial	12–20	41	26	North America	Government	Depression remission
Kobak et al., 2015 [48]	Psychosocial	12–17	65	12	North America	Government	Depressive symptom severity
Charkhandeh et al., 2016 [49]	Psychosocial	12–17	188	12	Asia	N/R^c	Depressive symptom severity
Cheung et al., 2016 [50]	Drug	13–18	25	24	North America	Government	Time to relapse
Kondo et al., 2016 [51]	Drug	13–20	33	8	North America	Government	Frontal lobe phosphocreatine levels
McCauley et al., 2016 [52]	Psychosocial	12–18	60	52	North America	Government; Hospital	Depressive symptom severity
Goodyer et al., 2017 [17]	Psychosocial	11–17	470	86	Europe	Government	Depressive symptom severity
Wunram et al., 2017 [53]	Physical Activity	13–18	64	26	Europe	Not for profit; Hospital	Depressive symptom severity

^aIntervention types categorized as follows: Drug (i.e., duloxetine, fluoxetine, citalopram, sertraline, escitalopram); Psychosocial (i.e., cognitive behavioural therapy, collaborative care intervention, supportive non-directive therapy, Reiki method); Physical activity (i.e., whole-body vibration, cardiovascular training)
^bFunding sources categorized as follows: Government: funded by a governmental organization (i.e., Canadian Institutes of Health Research, National Institute of Mental Health, National Institute for Health Research); Hospital: funded by hospital or university-affiliated research centre within hospital (i.e., University of Washington/Seattle Children’s Hospital Institute of Translational Health Sciences Pediatric Clinical Research Center); Industry: for profit corporation (i.e., Eli Lilly and Company, Somerset Pharmaceuticals Incorporated, Forest Laboratories); Not for profit: not for profit foundation or organization (i.e., Marga and Walter Boll Foundation, American Foundation for Suicide Prevention, St. Luke’s Foundation of Cleveland)
^cN/R: not reported

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com